Reversal of lactate and PD-1–mediated macrophage immunosuppression controls growth of PTEN/p53-deficient prostate cancer

K Chaudagar, HM Hieromnimon, R Khurana… - Clinical Cancer …, 2023 - AACR
Purpose: Phosphatase and tensin homolog (PTEN) loss of function occurs in approximately
50% of patients with metastatic castrate-resistant prostate cancer (mCRPC), and is …
被引用次数：31 相关文章

Reversal of lactate and PD-1-mediated macrophage immunosuppression controls growth of PTEN/p53-deficient prostate cancer

K Chaudagar, HM Hieromnimon, R Khurana… - bioRxiv, 2022 - biorxiv.org
PTEN loss-of-function occurs in approximately 50% of mCRPC patients, and is associated
with a poor prognosis, therapeutic outcomes and resistance to immune-checkpoint …

Reversal of Lactate and PD-1-mediated Macrophage Immunosuppression Controls Growth of PTEN/p53-deficient Prostate Cancer.

K Chaudagar, HM Hieromnimon… - … Cancer Research: an …, 2023 - europepmc.org
Purpose Phosphatase and tensin homolog (PTEN) loss of function occurs in approximately
50% of patients with metastatic castrate-resistant prostate cancer (mCRPC), and is …

Reversal of Lactate and PD-1–mediated Macrophage Immunosuppression Controls Growth of PTEN/p53-deficient Prostate Cancer

K Chaudagar, HM Hieromnimon, R Khurana… - Clinical Cancer …, 2023 - AACR
Purpose: Phosphatase and tensin homolog (PTEN) loss of function occurs in approximately
50% of patients with metastatic castrate-resistant prostate cancer (mCRPC), and is …

Reversal of lactate and PD-1-mediated macrophage immunosuppression controls growth of PTEN/p53-deficient prostate cancer

K Chaudagar, HM Hieromnimon… - Clinical cancer …, 2023 - scholarship.miami.edu
PURPOSEPTEN loss-of-function occurs in~ 50% of metastatic, castrate-resistant prostate
cancer (mCRPC) patients, and associated with poor prognosis and responsiveness to …
[PDF] archive.org

[PDF][PDF] Reversal of lactate and PD-1-mediated macrophage immunosuppression controls growth of PTEN/p53-deficient prostate cancer

K Chaudagar, HM Hieromnimon, R Khurana… - scholar.archive.org
PTEN loss-of-function occurs in approximately 50% of mCRPC patients, and is associated
with a poor prognosis, therapeutic outcomes and resistance to immune-checkpoint …
[HTML] nih.gov

[HTML][HTML] Reversal of lactate and PD-1-mediated macrophage immunosuppression controls growth of PTEN/p53-deficient prostate cancer

K Chaudagar, HM Hieromnimon… - … cancer research: an …, 2023 - ncbi.nlm.nih.gov
Purpose: PTEN loss-of-function occurs in~ 50% of metastatic, castrate-resistant prostate
cancer (mCRPC) patients, and associated with poor prognosis and responsiveness to …
[PDF] researchgate.net

[PDF][PDF] Reversal of lactate and PD-1-mediated macrophage immunosuppression controls growth of PTEN/p53-deficient prostate cancer

K Chaudagar, HM Hieromnimon, R Khurana… - researchgate.net
PTEN loss-of-function occurs in approximately 50% of mCRPC patients, and is associated
with a poor prognosis, therapeutic outcomes and resistance to immune-checkpoint …

Reversal of Lactate and PD-1-mediated Macrophage Immunosuppression Controls Growth of PTEN/p53-deficient Prostate Cancer

K Chaudagar, HM Hieromnimon… - … : an official journal …, 2023 - pubmed.ncbi.nlm.nih.gov
Purpose Phosphatase and tensin homolog (PTEN) loss of function occurs in approximately
50% of patients with metastatic castrate-resistant prostate cancer (mCRPC), and is …

Reversal of lactate and PD-1-mediated macrophage immunosuppression controls growth of PTEN/p53-deficient prostate cancer.

K Chaudagar, HM Hieromnimon… - … Cancer Research: an …, 2023 - europepmc.org
Purpose PTEN loss-of-function occurs in~ 50% of metastatic, castrate-resistant prostate
cancer (mCRPC) patients, and associated with poor prognosis and responsiveness to …